16th Dec 2019 09:21
(Alliance News) - Scancell Holdings PLC on Monday said it has signed a second collaboration and non-exclusive research agreement with an undisclosed Chinese biotechnology company.
The stock was 10% higher in London in morning trade at 5.40 pence a share.
The immunotherapies company said the collaboration was agreed to assess monoclonal antibodies targeting tumour-associated glycans that have been enhanced with its proprietary AvidiMab technology.
Under the terms, this new collaboration partner will conduct preclinical studies to evaluate Scancell's antibodies, including those enhanced with AvidiMab, for the treatment of cancer.
"We are pleased to announce this second collaboration agreement for the AvidiMab platform. As previously stated, we believe our novel AvidiMab platform and tumour associated glycan antibodies have broad partnering potential and this has been further demonstrated by today's agreement, the second in four months," said Chief Executive Cliff Holloway.
He added: "This is our first collaboration in China, and we look forward to updating the market on further progress with this platform in due course."
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings